Dopamine D 1 receptor deletion strongly reduces neurotoxic effects of methamphetamine

Neurobiology of Disease

Volumn 45, Issue 2, 2012, Pages 810-820

  Ares Santos, S ^a,b   Granado, N ^a,c   Oliva, I ^d   O'Shea, E ^c   Martin, E D ^d   Colado, M I ^c   Moratalla, R ^a,b  

^a INSTITUTO CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d Universidad Castilla La Mancha   (Spain)

Author keywords

Amphetamine derivatives; DAT; Dopamine overflow; Dopamine toxicity; Drug addiction; Glia; Parkinson's disease; Striatum; Substantia nigra; TH

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; DOPAMINE 1 RECEPTOR; HOMOVANILLIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; METHAMPHETAMINE; METIROSINE; RESERPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; CYCLIC POTENTIOMETRY; CYTOSOL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ELECTROSTIMULATION; ENVIRONMENTAL TEMPERATURE; FEMALE; GENE DELETION; GLIOSIS; HIGH TEMPERATURE; HYPERTHERMIA; KNOCKOUT MOUSE; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SUBSTANTIA NIGRA; WILD TYPE;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; FEMALE; FEVER; IMMUNOHISTOCHEMISTRY; MALE; METHAMPHETAMINE; MICE; MICE, KNOCKOUT; RECEPTORS, DOPAMINE D1;

EID: 84855817735     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.11.005     Document Type: Article

References (69)

1. Achat-Mendes C., Ali S.F., Itzhak Y. Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice. Neuropsychopharmacology 2005, 30:1128-1137.
2. Albers D.S., Sonsalla P.K. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther. 1995, 275:1104-1114.
3. Anderson K.L., Itzhak Y. Methamphetamine-induced selective dopaminergic neurotoxicity is accompanied by an increase in striatal nitrate in the mouse. Ann. N. Y. Acad. Sci. 2006, 1074:225-233.
4. Angulo J.A., Angulo N., Yu J. Antagonists of the neurokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum. Ann. N. Y. Acad. Sci. 2004, 1025:171-180.
5. Block M.L., Hong J.S. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem. Soc. Trans. 2007, 35:1127-1132.
6. Bowyer J.F., Robinson B., Ali S., Schmued L.C. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse 2008, 62:193-204.
7. Boyle N.T., Connor T.J. Methylenedioxymethamphetamine ('Ecstasy')-induced immunosuppression: a cause for concern?. Br. J. Pharmacol. 2010, 161:17-32. Review.
8. Broening H.W., Morford L.L., Vorhees C.V. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 2005, 56:84-93.
9. Bronstein D.M., Hong J.S. Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. J. Pharmacol. Exp. Ther. 1995, 274:943-950.
10. Bull D.R., Palij P., Sheehan M.J., Millar J., Stamford J.Á., Kruk Z.L., et al. Application of fast cyclic voltammetry to measurement of electrically dopamine overflow from brain slices in vitro. J. Neurosci. Meth. 1990, 32:37-44.
11. Cadet J.L., Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. 1998, 32:117-131.
12. Cadet J.L., Krasnova I.N. Molecular bases of methamphetamine-induced neurodegeneration. Int. Rev. Neurobiol. 2009, 88:101-119.
13. Cadet J.L., Ali S., Epstein C. Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: evidence from the use of CuZnSOD transgenic mice. Ann. N. Y. Acad. Sci. 1994, 738:388-391.
14. Cadet J.L., Jayanthi S., Deng X. Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Neurotox. Res. 2005, 8:199-206.
15. Cadet J.L., Krasnova I.N., Jayanthi S., Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox. Res. 2007, 11:183-202.
16. Chen J., Rusnak M., Luedtke R.R., Sidhu A. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J. Biol. Chem. 2004, 279:39317-39330.
17. Darmopil S., Muñetón-Gómez V.C., de Ceballos M.L., Bernson M., Moratalla R. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA. Eur. J. Neurosci. 2008, 27:580-592.
18. Darmopil S., Martín A.B., De Diego I.R., Ares S., Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol. Psychiatry 2009, 66:603-613.
19. Dawson T.M. Parkin and defective ubiquitination in Parkinson's disease. J. Neural Transm. Suppl. 2006, 209-213.
20. Deng X., Ladenheim B., Tsao L.I., Cadet J.L. Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J. Neurosci. 1999, 15(19):10107-10115.
21. Fantegrossi W.E., Ciullo J.R., Wakabayashi K.T., De La G.R., Traynor J.R., Woods J.H. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 2008, 151:533-543.
22. Fumagalli F., Gainetdinov R.R., Valenzano K.J., Caron M.G. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 1998, 1(18):4861-4869.
23. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., Caron M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 1999, 19:2424-2431.
24. Granado N., Escobedo I., O'Shea E., Colado M.I., Moratalla R. Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse 2008, 62:80-84.
25. Granado N., Ortiz O., Suarez L.M., Martin E.D., Cena V., Solis J.M., et al. D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-induced arc and zif268 expression in the hippocampus. Cereb. Cortex 2008, 18:1-12.
26. Granado N., O'Shea E., Bove J., Vila M., Colado M.I., Moratalla R. Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J. Neurochem. 2008, 107:1102-1112.
27. Granado N., Ares-Santos S., O'Shea E., Vicario-Abejon C., Colado M.I., Moratalla R. Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine. Neurotox. Res. 2010, 18:48-58.
28. Granado N., Lastres-Becker I., Ares-Santos S., Oliva I., Martin E.D., Cuadrado A., Moratalla R. Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia 2011, 10.1002/glia.21229.
29. Granado N., Ares-Santos S., Oliva I., OD́Shea E., Martin E.D., Colado M.I., et al. Dopamine D2R knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol. Dis. 2011, 42:391-403.
30. Gutierrez-Lopez M.D., Llopis N., Feng S., Barret D.A., O'Shea E., Colado M.I. Involvement of 2-arachidonoyl glycerol in the increases consumption of and preference for ethanol of mice treated with neurotoxic doses of methamphetamine. Br. J. Pharmacol. 2010, 160:772-783. 2010 Jun.
31. Imam S.Z., el-Yazal J., Newport G.D., Itzhak Y., Cadet J.L., Slikker W., et al. Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann. N. Y. Acad. Sci. 2001, 939:366-380. Review.
32. Jaber M., Dumartin B., Sagné C., Haycock J.W., Roubert C., Giros B., et al. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Eur. J. Neurosci. 1999, 11:3499-34511.
33. Jackson-Lewis V., Vila M., Djaldetti R., Guegan C., Liberatore G., Liu J., et al. J. Comp. Neurol. 2000, 424:476-488.
34. Jayanthi S., Deng X., Ladenheim B., McCoy M.T., Cluster A., Cai N.S., et al. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:868-873.
35. Jayanthi S., McCoy M.T., Beauvais G., Ladenheim B., Gilmore K., Wood W., et al. Methamphetamine induces dopamine D1 receptor-dependent endoplasmic reticulum stress-related molecular events in the rat striatum. PLoS One 2009, 4:e6092.
36. Jia Z., Zhu H., Li Y., Misra H.P. Cruciferous nutraceutical 3H-1,2-dithiole-3-thione protects human primary astrocytes against neurocytotoxicity elicited by MPTP, MPP(+), 6-OHDA, HNE and acrolein. Neurochem. Res. 2009, 34:1924-1934.
37. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4029-4034.
38. Kil H.Y., Zhang J., Piantadosi C.A. Brain temperature alters hydroxyl radical production during cerebral ischemia/reperfusion in rats. J. Cereb. Blood Flow Metab. 1996, 16:100-106.
39. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60:379-407.
40. Krasnova I.N., Ladenheim B., Hodges A.B., Volkow N.D., Cadet J.L. Chronic methamphetamine administration causes differential regulation of transcription factors in the rat midbrain. PLoS One 2011, 25(6):e19179.
41. LaVoie M.J., Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 1999, 19:1484-1491.
42. Martín E.D., Buño W. Stabilizing effects of extracellular ATP on synaptic efficacy and plasticity in hippocampal pyramidal neurons. Eur. J. Neurosci. 2005, 21:936-944.
43. McCann U.D., Wong D.F., Yokoi F., Villemagne V., Dannals R.F., Ricaurte G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci. 1998, 18:8417-8422.
44. Metzger R.R., Haughey H.M., Wilkins D.G., Gibb J.W., Hanson G.R., Fleckenstein A.E. Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J. Pharmacol. Exp. Ther. 2000, 295:1077-1085.
45. Moratalla R., Xu M., Tonegawa S., Graybiel A.M. Cellular responses to psychomotor stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine receptor. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14928-14933.
46. O'Callaghan J.P., Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 1994, 270:741-751.
47. O'Dell S.J., Weihmuller F.B., Marshall J.F. Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: attenuation by dopamine D1 or D2 antagonists. J. Neurochem. 1993, 60:1792-1799.
48. -/- mice and in hippocampal siRNA silenced Drd1a mice. J. Neurosci. 2010, 30:12288-12300.
49. Pavon N., Martin A.B., Mendialdua A., Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 2006, 59:64-74.
50. Seiden L.S., Fischman M.W., Schuster C.R. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend. 1976, 1:215-219.
51. Sonsalla P.K., Gibb J.W., Hanson G.R. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J. Pharmacol. Exp. Ther. 1986, 238:932-937.
52. Sonsalla P.K., Jochnowitz N.D., Zeevalk G.D., Oostveen J.A., Hall E.D. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 1996, 738:172-175.
53. Spencer J.P., Whiteman M., Jenner P., Halliwell B. 5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J. Neurochem. 2002, 81:122-129.
54. Sriram K., Miller D.B., O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 2006, 96:706-718.
55. Tata D.A., Raudensky J., Yamamoto B.K. Augmentation of methamphetamine induced toxicity in the rat striatum by unpredictable stress: contribution of enhanced hyperthermia. Eur. J. Neurosci. 2007, 26:739-748.
56. Thomas D.M., Dowgiert J., Geddes T.J., Francescutti-Verbeem D., Liu X., Kuhn D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 2004, 367:349-354.
57. Thomas D.M., Francescutti-Verbeem D.M., Kuhn D.M. Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling. J. Neurochem. 2008, 106:696-705.
58. Thomas D.M., Francescutti-Verbeem D.M., Kuhn D.M. The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J. Neurochem. 2008, 105:605-616.
59. Tinsley R.B., Bye C.R., Parish C.L., Tziotis-Vais A., George S., Culvenor J.G., et al. Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann. Neurol. 2009, 66:472-484.
60. UNODC, World Drug Report United Nations Publication, Sales No.E.10.XI.13 2010.
61. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 2001, 21:9414-9418.
62. Volz T.J., Hanson G.R., Fleckenstein A.E. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. J. Neurosci. Methods 2006, 155:109-115.
63. Wightman R.M., Zimmerman J.B. Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake. Brain Res. Rev. 1990, 15:135-144.
64. Xie T., McCann U.D., Kim S., Yuan J., Ricaurte G.A. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J. Neurosci. 2000, 20:7838-7845.
65. Xu M., Moratalla R., Gold L.H., Hiroi N., Koob G.F., Graybiel A.M., et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 1994, 79:729-742.
66. Xu W., Zhu J.P., Angulo J.A. Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. Synapse 2005, 58:110-121.
67. Yamamoto B.K., Moszczynska A., Gudelsky G.A. Amphetamine toxicities: classical and emerging mechanisms. Ann. N. Y. Acad. Sci. 2010, 1187:101-121.
68. Zhang L., Shirayama Y., Shimizu E., Iyo M., Hashimoto K. Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur. J. Pharmacol. 2006, 44:1-3.
69. Zhu J.P., Xu W., Angulo J.A. Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice. Brain Res. 2005, 1049:171-181.